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Abstract
Purpose To assess correlations between the degree of dopa-
minergic depletion measured using single-photon emission
computed tomography (SPECT) and different clinical param-
eters of disease progression in Parkinson’s disease (PD).
Methods This retrospective study included 970 consecutive
patients undergoing 123I-ioflupane SPECT scans in our insti-
tution between 2003 and 2013, from which we selected a
study population of 411 patients according to their clinical
diagnosis: 301 patients with PD (69.4±11.0 years, of age,
163 men) and 110 patients with nondegenerative conditions
included as controls (72.7±8.0 years of age, 55 men). Com-
prehensive and operator-independent data analysis included
spatial normalization into standard space, estimation of the
mean uptake values in the striatum (caudate nucleus + puta-
men) and voxel-wise correlation between SPECTsignal inten-
sity and disease stage as well as disease duration in order to
investigate the spatiotemporal pattern of the dopaminergic
nigrostriatal degeneration. To compensate for potential inter-
actions between disease stage and disease duration, one pa-
rameter was used as nonexplanatory coregressor for the other.
Results Increasing disease stage was associated with an expo-
nential decrease in 123I-ioflupane uptake (R2=0.1501)
particularly in the head of the ipsilateral caudate nucleus
(p<0.0001), whereas increasing disease duration was associ-
ated with a linear decrease in 123I-ioflupane uptake
(p<0.0001; R2=0.1532) particularly in the contralateral ante-
rior putamen (p<0.0001).
Keypoints • Disease stage and disease duration have different
spatiotemporal patterns of dopaminergic depletion in PD.
• 123I-Ioflupane uptake in the striatum decreases exponentially with
disease stages.
• Disease stage correlates particularly with uptake in the head of the
caudate nucleus with ipsilateral predominance.
• 123I-ioflupane uptake in the striatum decreases linearly with disease
duration.
• Disease duration correlates particularly with uptake in the anterior
putamen with contralateral predominance.
• The operator-independent spatial normalization of 123I-ioflupane
SPECTscans provides a reference database for research and clinical stud-
ies based on a large sample of 411 patients.
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Conclusion We observed two distinct spatiotemporal patterns
of posterior to anterior dopaminergic depletion associated
with disease stage and disease duration in patients with PD.
The developed operator-independent reference database of
411 123I-ioflupane SPECT scans can be used for clinical and
research applications.
Keywords Parkinson’s disease . 123I-ioflupane SPECT .
Voxel-wise analysis . Disease duration . Disease stage
Introduction
Over the last two decades, 123I-ioflupane SPECT has
become a routinely used tool for the diagnosis of
Parkinson’s disease (PD). It has proved particularly use-
ful in distinguishing PD and other degenerative forms of
parkinsonism from nondegenerative movement disorders
such as essential tremor, dystonia, drug-induced parkin-
sonism and many others [1–6]. It may also serve as a
powerful instrument for the in vivo clinical investigation
of the pathophysiological mechanisms underlying this
neurodegenerative disorder. The technique involves a ra-
dioactive ligand (123I-ioflupane) of the presynaptic dopa-
mine transporter (DAT), which has been shown to reflect
degeneration of the dopaminergic nigrostriatal pathway
in PD [3, 7, 8]. More recently, several investigations
have assessed a potential link between 123I-ioflupane
SPECT data and progression of PD, and have shown a
negative correlation between striatal 123I-ioflupane up-
take and disease stage [3, 7, 9–11]. However, most of
these studies included a relatively limited number of pa-
tients (16 PD vs. 10 controls [7], 41 PD [9], 32 PD vs.
24 controls [10], 19 PD [11], 103 PD [3]) and analysed
manually defined regions of interest (ROI).
Our present study included a unique cohort of 301 PD and
110 control patients identified from among 970 consecutive
patients scanned using the same SPECTapparatus and follow-
ing the same acquisition protocol in our institution between
2003 and 2013.We conducted an operator-independent voxel-
wise analysis in order to evaluate the correlation between
striatal uptake of 123I-ioflupane and disease duration and dis-
ease stage in patients with PD at a high spatial resolution.
Materials and methods
Participants
The local ethics committee approved this retrospective study,
which included 970 patients who had consecutively under-
gone a brain 123I-ioflupane SPECT scan in our institution be-
tween October 2003 and September 2013. From this cohort,
we identified 411 patients who met the following criteria: (1) a
visually assessed brain 123I-ioflupane SPECT scan, (2) exten-
sive neurological testing and follow-up, (3) a well-established
diagnosis of PD (patient group) or a neurological disorder
known to spare the nigrostriatal dopaminergic system (control
group), and (4) the absence of structural abnormalities on
brain MRI.
In the PD group, the diagnosis was established by a
trained movement disorders specialist following the UK
Parkinson’s Disease Society Brain Bank criteria. Criteria
included the presence of bradykinesia associated with at
least one of the following three criteria: 4–6 Hz resting
tremor, rigidity or postural instability. Supportive fea-
tures included, among others, unilateral onset, progres-
sive course, an excellent and sustained response to levo-
dopa or typical levodopa-induced dyskinesia. Of note,
patients exhibiting atypical features suggesting another
form of degenerative parkinsonism, such as multiple sys-
tem atrophy, progress ive supranuclear palsy or
corticobasal degeneration, or secondary parkinsonism
such as vascular parkinsonism or normal pressure hydro-
cephalus were all excluded. Importantly, while 123I-
ioflupane SPECT data were not used to establish a spe-
cific diagnosis of PD, an abnormal scan was required to
confirm degenerative parkinsonism. Accordingly, in the
PD group,123I-ioflupane SPECT typically showed an
asymmetrical reduction in striatal uptake more marked
in the putamen than in the caudate nucleus. PD patients
were staged according to the Hoehn and Yahr (H&Y)
classification, from mild and unilateral (stage 1) to ad-
vanced and bilateral disease stages (stages 4 and 5) [12].
The control group included patients who had had a 123 I-
ioflupane SPECT scan to assess an unusual tremor, un-
clear parkinsonism or other movement disorder of uncer-
tain origin, and whose scan turned out to be normal. This
control group therefore included patients with essential
tremor, drug-induced parkinsonism, psychogenic parkin-
sonism and various conditions known to be associated
with an unaltered nigrostriatal pathway.
Demographic and clinical data
The control group comprised 110 patients (age 72.7±
8.0 years, 55 men). The patient group comprised 301
PD patients stratified as follows: H&Y stage 1 (43 pa-
tients), H&Y stage 2 (142 patients), H&Y stage 3 (83
patients), H&Y stage 4 (19 patients) and H&Y stage 5
(13 patients; Table 1). As expected, there were signifi-
cant differences between adjacent groups regarding age
except between group H&Y stage 3 and 4 (p=0.471) and
between H&Y stage 4 and 5 (p=0.965). Statistical anal-
ysis did not reveal any significant differences among the
groups in terms of gender.
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SPECT image acquisition
After blocking thyroid uptake with either Lugol solution
or sodium perchlorate, about 185 MBq of 123I-FP-CIT
was administered intravenously. SPECT images were ac-
quired 4 h after injection on a triple-head gamma camera
(Toshiba Medical Systems, Tokyo, Japan) and fan-beam,
low-energy, high-resolution collimators. Images were ac-
quired in steps of 6° over 360° and a 128×128 matrix.
Patients were positioned using a head holder to minimize
head motion. Images were corrected for scatter using a
triple-energy window method and for photon attenuation
using a 0.15/cm uniform coefficient. Dopaminergic
agents were not discontinued. All images were recon-
structed using Toshiba GMS software version 5 with
the same reconstruction algorithms and parameters. More
details have been provided by Garibotto et al. [13].
MR image acquisition
MR imaging was performed over a period of 10 years as
part of routine clinical work-up. This explains the vari-
able MR protocol, but all patients had at least T2 imag-
ing, fluid attenuation inversion recovery imaging and
diffusion-weighted imaging or diffusion tensor imaging
to rule out structural brain lesions. Moreover, white mat-
ter lesions were assessed according to the Fazekas scale
[14]. A group of 103 patients had an additional high-
resolution Magnetization Prepared Rapid Gradient Echo
(MPRAGE) 3D T1 brain magnetic resonance scan as part
of clinical routine using a 3.0-T MR system (Magnetom
Trio; Siemens, Erlangen Germany) with the following
parameters 256×256 matrix, 176 sections, 1×1×1 mm,
TE=2.3 ms, TR=2.300 ms.
Statistical analysis
Statistical analyses were performed with GraphPad
Prism (version 6.0, www.graphpad.com) and FSL
(FMRIB Software Library, version 5.0, http://fsl.fmrib.
ox.ac.uk/fsl/fslwiki).
Image postprocessing
In a first step, we created a 123I-ioflupane-specific template
based on 103 patients who had both a 123I-ioflupane SPECT
and a 3D T1MPRAGEMRI scan. Each individual brain 123I-
ioflupane scan was linearly registered to the same patient 3D
T1 data using FLIRT (FMRIB’s linear image registration tool,
part of FSL) [15, 16] and 6° of motion. Additionally, the 3D
T1 data from individual patients were nonlinearly registered to
the Montreal neurological institute (MNI) standard space by
running FNIRT (part of FSL). This nonlinear transformation
matrix was then applied to the individual 123I-ioflupane scans.
Finally, a 123I-ioflupane-specific template was generated by
merging and averaging all 123I-ioflupane images (using
fslmerge and fslmeants, parts of FSL). In summary, this pro-
cedure created a nonlinear spatial normalization of the 123I-
ioflupane scan into standard space using the information from
the 3DT1 high-resolutionMRI imaging in individual patients.
Similar procedures have been used successfully in previous
investigations [17, 18].
In a second step, all individual 123I-ioflupane SPECT scans
were spatially normalized to this 123I-ioflupane SPECT tem-
plate. In addition to the spatial normalization, the 123I-
ioflupane SPECT scans were also intensity normalized by
subtracting the average signal in the occipital region as refer-
ence region to each individual 123I-ioflupane data by using
fslmaths (part of FSL). The resulting images were then divid-
ed by the average signal of the occipital region as described by
Garibotto et al. [13]. The occipital region mask was manually
c r e a t e d u s i n g f s l v i ew ( p a r t o f F SL ) o n t h e
MNI152_T1_2mm_brain template.
To take into account the asymmetrical nature of PD,
using fslswapdim we flipped images in patients with pre-
dominantly left-sided clinical symptoms to have the clin-
ical predominance of the disease on the same side, so
that the right side of the images corresponded to the
Table 1 Demographic and clinical characteristics
Control
group
Hoehn and Yahr stage
1 2 3 4 5
Sex (m/f) 55/55 18/25 (n.s. vs. control) 85/58 (n.s. vs. stage 1) 42/41 (n.s. vs. stage 2) 9/10 (n.s. vs. stage 3) 9/4 (n.s. vs. stage 4)
Age (years) 72.7±8.0 62.3±11.3
(p<0.01 vs. control)
67.8±10.9
(p<0.05 vs. stage 1)
73.5±8.9
(p<0.001 vs. stage 2)
75.2±10.2
(n.s. vs. stage 3)
75±9.5
(n.s. vs. stage 4)
Disease duration
(years)
– 2.1±2.3 3.8±5.0 5.1±4.4 5.3±4.7 7.1±6.0
n.s. not significant
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clinically less affected body side and the left side to the
more affected body side in all subjects including con-
trols. This was done after spatial normalization.
Analysis of mean 123I-ioflupane uptake
The mean 123I-ioflupane uptake values were calculated
using a mask of the striatum. This striatal mask was
created using the Harvard Oxford subcortical atlas (in-
cluded in FSL) by combining the regions of the left and
right putamen and caudate nucleus using fslmaths. The
patients were grouped according to disease stage (de-
fined as the H&Y stage at the time of image acquisition)
and disease duration according to the time elapsed be-
tween the appearance of the first PD symptom and image
acquisition and as described below (Table 2). The mean
123I-ioflupane uptakes in the striatal mask were calculat-
ed for each group as well as for controls using fslmeants.
Linear and nonlinear regression was applied to the mean
values (exponential one-decay linear regression). Note
that the control values were not taken into account by
the software for the operations described above.
Voxel-wise analysis of 123I-ioflupane uptake
Voxel-wise analysis was performed by permutation test-
ing (n=5,000) using the randomise function (part of
FSL) and Threshold-Free Cluster Enhancement (TFCE)
error considering multiple comparison corrected p values
<0.05 corrected as significant [19]. The analysis was run
for both disease stage according to the H&Y stage and
disease duration in years since the first identified PD
symptom, investigating positive and negative linear cor-
relations. Note that for the correlation with disease dura-
tion, disease stage was used as a nonexplanatory
coregressor to compensate for a potentially confounding
effect of disease duration. The analysis was done simi-
larly for disease stage. Moreover, age and gender were
used as coregressors to compensate for potential effects
of age and gender. To assess the laterality of these re-
sults, we compared the voxel values in the striatum be-
tween the ipsilateral (right) side and the contralateral
(left) side for disease stage and disease duration using
unpaired t tests. In order not to bias the results, the sta-
tistical analysis did not include the control group.
Results
Analysis of mean 123I-ioflupane uptake
Evolution of the average 123I-ioflupane uptake showed a
posterior to anterior progression of the dopaminergic de-
pletion in the striatum, particularly the putamen, related
to disease stage (Fig. 1, top) and duration (Fig. 1, bot-
tom), but with two distinct patterns. We found an expo-
nential decrease in 123I-ioflupane uptakes with progres-
sive disease stage (R2=0.1509). Conversely, the 123I-
ioflupane uptakes decreased linearly with progressive
disease duration (p<0.0001; R2=0.1532).
Voxel-wise analysis of 123I-ioflupane uptake
The voxel-wise analysis revealed two different spatiotemporal
patterns of 123I-ioflupane uptake with increasing disease du-
ration and disease stage. Increasing disease duration correlated
with decreased uptake particularly in the anterior part of the
putamen with a contralateral predominance (p<0.0001). Con-
versely, increasing disease stage was correlated with de-
creased 123I-ioflupane uptake particularly in the head of the
caudate nucleus with an ipsilateral predominance (p<0.0001).
The voxel-wise analyses of disease duration and disease stage
were performed using the other parameter as coregressor in
order to exclude potentially confounding interactions between
these two factors (Fig. 2).
Discussion
We developed an operator-independent database of 123I-
ioflupane scans for research and clinical studies based on a
large sample of 301 consecutive PD patients and 110 controls
who underwent extensive neurological evaluation and follow-
up. Using this reference database, we demonstrated two
Table 2 Patient grouping
Disease duration Disease stage
Duration (years) Group No. of patients H&Y stage Group No. of patients
0–1 1 99 1 1 43
1.25–2 2 61 2 2 143
2.5–5 3 62 3 3 83
6–9 4 42 4 4 19
>10 5 37 5 5 13
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distinct spatiotemporal patterns of dopaminergic depletion in
PD. Overall, both disease duration and disease stage were
associatedwith progressive dopaminergic depletion in the stri-
atum, particularly the putamen, with a posterior to anterior
gradient, in accordance with the findings of many previous
studies. Interestingly, we found that increasing disease stage
was associated with an exponential dopaminergic depletion
particularly in the ipsilateral head of the caudate nucleus,
while increasing disease duration was associated with linear
dopaminergic depletion particularly in the contralateral ante-
rior putamen.
Disease stage
During the past two decades, several molecular imaging stud-
ies have assessed the link between progression of PD and
degeneration of the nigrostriatal dopaminergic system [3, 7,
9–11]. Most have observed a correlation between disease
Fig. 1 Mean 123I-ioflupane uptake as a function of increasing Hoehn and
Yahr disease stage (top) and increasing disease duration (bottom)
superimposed on the Montreal Neurological Institute (MNI) standard
space (T1 2-mm brain transverse section, z=4). Top The normalized in-
tensities range from 1 (low intensity, red) to 3 (high intensity. yellow).
123I-Ioflupane uptake decreases exponentially (R2=0.1501) with increas-
ing Hoehn and Yahr stage. Bottom The normalized intensities range from
1 (dark blue) to 3 (light blue). 123I-Ioflupane uptake decreases linearly
with disease duration (p<0.0001, R2=0.1532; group 1 short disease du-
ration, group 5 long disease duration)
Fig. 2 Correlations
corresponding to Hoehn and Yahr
stage (red) and disease duration
(blue) superimposed on the
Montreal Neurological Institute
(MNI) standard space (T1 2-mm
brain transverse section, z=4, and
coronal section, y=12)
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stage and deterioration of the signal obtained by in vivo neu-
roimaging assessment of the dopaminergic system either with
18F-Dopa PET or with SPECT [3, 9, 10, 20–22], yet a few
studies have failed to confirm this correlation [23, 24]. Over-
all, in our study, we definitely observed a clear posterior to
anterior progression of dopaminergic depletion with increas-
ing disease stage, in agreement with the findings of previous
investigations [3, 25, 26]. Interestingly, Benamer et al.
assessed 41 PD patients with Hoehn and Yahr stages I to IV
and found a linear decrease in mean striatal uptake with in-
creasing disease stage based on a ROI approach in a cross-
sectional design [9]. Our results, obtained in a much larger
cohort of 301 PD patients and an operator-independent vox-
el-wise analysis, in contrast demonstrated an exponential de-
crease in striatal uptake. This difference might be related to
different scales for rating disease stage. Indeed, while
Benamer et al. [9] used the Unified Parkinson’s Disease Rat-
ing Score (UPDRS), we used the H&Y staging system, which
is far less sensitive to the effects of levodopa and other
antiparkinsonian medications.
The exponential decrease in striatal uptake with progres-
sive disease stage indicates a faster dopaminergic depletion in
early than inmore advanced disease stages, following a steady
percentage of neuronal loss or a variable absolute value of
loss, more marked in the early phase of the condition. It is
noteworthy that the few neuropathological investigations that
have addressed this issue have indicated that the neuronal loss
occurring in the PD substantia nigra pars compacta seems to
follow a nonlinear exponential profile, as in our study, where-
by neuronal loss within the nigrostriatal system is massive
during the first few years after disease initiation and far less
pronounced afterwards [27, 28]. The large variability in the
data presented in Fig. 1b, d reflects the substantial interindi-
vidual variability of PD, as discussed by Benamer et al. [9].
In the majority of the investigations discussed above
ROI analysis was used, and this, because of poor spatial
resolution, may have biased the results. As a novel find-
ing, the operator-independent voxel-wise analysis applied
in this large cohort was able to show that uptake in the
head of the caudate nucleus appears to be correlated with
disease stage. This unexpected yet robust finding suggests
that the anterior striatum is also the site of an intense and
active degenerative process that takes place in more ad-
vanced stages of the disease, whereas the posterior stria-
tum sustains massive neurodegeneration earlier in the dis-
ease course, as supported by the nonlinear decrease in the
reduction of 123I-ioflupane uptake. In addition, at later
stages, there might be a floor effect whereby ligand up-
take is so low that a further reduction may no longer be
captured. This finding is clinically meaningful as the cau-
date nucleus is essentially involved in the associative loop
of the basal ganglia circuitry, and may well play an im-
portant role in late cognitive features of PD, including
executive dysfunction that is found in the vast majority
of patients, apathy, memory loss, cognitive decline and,
eventually, overt dementia.
Disease duration
In contrast to disease stage, few previous studies have inves-
tigated the correlation between striatal uptake and disease du-
ration. Overall, increasing disease duration was again associ-
ated with a posterior to anterior decrease in striatal 123I-
ioflupane striatal uptake. In a longitudinal ROI-based study
in 32 PD patients and 24 controls, Marek et al. found a linear
decrease in striatal 123I-β-CIT uptake [10]. Our operator-
independent analysis reproduced this linear decrease in dopa-
minergic depletion in PD patients with increasing disease du-
ration. As an additional finding, voxel-wise correlation anal-
ysis showed that the anterior part of the putamen was progres-
sively impaired with increasing disease duration, which, as
discussed in the previous section, can also be interpreted as
a later step in the nigrostriatal degenerative process, whereby
as structures become more affected with disease progression
following a caudorostral gradient, the precommissural stria-
tum undergoes rapid and severe degeneration later than the
postcommissural striatum where the degenerative process
has already slowed down.
Laterality
While it is commonly accepted that there is a good correlation
between the body side more affected by parkinsonism and a
more marked contralateral decrease in striatal uptake, some
previous investigations have shown partially conflicting re-
sults regarding the laterality of the dopaminergic depletion
[4, 7, 9, 11]. In the current study, we disentangled the interac-
tion of disease stage and duration. We were able to demon-
strate that increasing disease stage was correlated with a pre-
dominantly ipsilateral dopaminergic depletion particularly in
the head of the caudate nucleus, while increasing disease du-
ration was correlated with predominantly contralateral dopa-
minergic depletion particularly in the anterior putamen. This
complex interaction between disease stage and duration,
which was not compensated for in the investigations discussed
above, might explain the partially conflicting results among
the previous studies.
Strengths and limitations
The major strength of this study is the large sample size of 301
consecutive PD patients and 110 controls who were all
scanned in the same institution using the same protocol and
machine. Moreover, all postprocessing steps were operator-
independent, resulting in a reference database for clinical
and research applications. In order to compensate for
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potentially confounding effects between disease duration and
disease stage, we used the other parameter as a nonexplanato-
ry coregressor, i.e. analysing duration and controlling for
stage, and vice versa. Additionally, we used gender and age
as additional coregressor to compensate for the well-known
dopaminergic depletion linked to ageing [22, 24, 29, 30].
We used the H&Y scale [12] to assess disease stage.
This scale was established in 1967 in a very large cohort
of PD patients who were followed over 15 years at a
time when no effective treatment for PD was available.
Thus, the H&Y scale reflects the natural course of PD
independently of any therapeutic intervention. This five-
stage scale is easy to use and is therefore considered by
many movement disorder experts a robust scale to follow
disease progression, especially in later stages of the con-
dition. On the other hand, the UPDRS [31] was devel-
oped as a comprehensive instrument for the evaluation of
impairment and disability at a certain time point so that
outcomes among different clinical trials or any therapeu-
tic interventions could be directly compared. The
UPDRS is highly sensitive to dopaminergic treatments
and levodopa-responsive symptoms are particularly
weighted. Consequently, as the vast majority of our pa-
tients were chronically treated with antiparkinsonian
medications, and because an off-medication UPDRS
score was not available at the time of the scan, we de-
cided to rely on the H&Y staging system as a measure of
disease progression as it better reflects the long-term
stage of the disease and is less influenced by current
medication. It is noteworthy, however, that there is as
yet no ideal, validated and medication-insensitive clini-
cal scale specifically dedicated to the measurement of
disease progression in PD.
A limitation of the current investigation was its retrospec-
tive nature and the fact that patients were included from a
clinical setting with a nonstandardized clinical work-up. The
variable exposure to symptomatic medication in this clinical
study might have been another potential bias. However, sev-
eral studies have shown that standard antiparkinsonian treat-
ment does not significantly affect the data obtained by 123I-
ioflupane SPECT [32–34]. A previous multicentre study
assessed 139 healthy controls [35] and another related study
from the same multicentre database assessed 122 healthy con-
trols focusing notably on ageing and gender differences [36].
In contrast to these studies, our database includes controls
and patients, and provides a voxel-wise rather than a region-
based analysis.
Finally, we believe that the findings of this study
may be clinically useful and may help clarify some
problematic situations at the bedside, for example dis-
crepancies between the patient’s perception of symptoms
and the SPECT data, development of PD-related cogni-
tive decline versus cognitive symptoms as side effects
of medication or even perhaps distinguishing between
the various degenerative forms of parkinsonism.
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